Treatment sequencing in metastatic colorectal cancer

Nanteznta Torounidou; Melina Yerolatsite; George Zarkavelis; Anna-Lea Amylidi; Vaia Karafousia; Eleftherios Kampletsas; Davide Mauri

doi:10.5114/wo.2024.146982

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2024
vol. 28

Send email

Copy url:

abstract:

Review paper

Treatment sequencing in metastatic colorectal cancer

Nanteznta Torounidou

¹

,

Melina Yerolatsite

¹

,

George Zarkavelis

^{1, 2}

,

Anna-Lea Amylidi

¹

,

Vaia Karafousia

¹

,

Eleftherios Kampletsas

^{1, 2}

,

Davide Mauri

^{1, 2}

Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece
Society for Study of Clonal Heterogeneity of Neoplasia (EMEKEN), Ioannina, Greece

Contemp Oncol (Pozn) 2024; 28 (4): 283–290

DOI: https://doi.org/10.5114/wo.2024.146982

Online publish date: 2025/01/15

View full text Get citation

PlumX metrics:

Metastatic colorectal cancer (mCRC) remains a significant challenge in contemporary oncology, with treatment sequencing playing a pivotal role in reported patient outcomes. Although currently available therapeutic options have led to improved median overall survival rates, the prognosis for patients with stage IV disease still remains dismal. This article provides a comprehensive review of the current landscape of treatment sequencing strategies in mCRC, focusing on the rationale behind various approaches and the evolving evidence supporting their efficacy. We consider the roles of chemotherapy, targeted therapy, and immunotherapy agents, as well as emerging trends in personalized medicine and sequential therapy regimens. The concept of a “continuum of care” has emerged as a fundamental principle, aiming to provide all available therapies through an individualized approach to maximize clinical benefit. By elucidating the underlying complexities of treatment sequencing in mCRC, this review aims to guide clinicians in optimizing therapeutic strategies and improving patient care.

keywords:

Treatment sequencing in metastatic colorectal cancer

Nanteznta Torounidou 1 , Melina Yerolatsite 1 , George Zarkavelis 1, 2 , Anna-Lea Amylidi 1 , Vaia Karafousia 1 , Eleftherios Kampletsas 1, 2 , Davide Mauri 1, 2

metastatic colorectal cancer, targeted therapy sequencing, immunotherapy sequencing, personalized therapy

Nanteznta Torounidou

¹

,

Melina Yerolatsite

¹

,

George Zarkavelis

^{1, 2}

,

Anna-Lea Amylidi

¹

,

Vaia Karafousia

¹

,

Eleftherios Kampletsas

^{1, 2}

,

Davide Mauri

^{1, 2}